Nanoscale delivery is a general solution to a specific problem: getting an active molecule to the right place intact. Here is where our partners are applying it today.
01 / Oncology
Charge-shifting surfaces stay stealthy at physiological pH and become adhesive in the acidic tumour microenvironment. In orthotopic models this raised intratumoural payload concentration 6.2× versus untargeted carriers while liver accumulation fell by half.
Read more — Oncology02 / Immunology & vaccines
Lyophilisation-compatible lipid shells protect self-amplifying RNA through reconstitution, keeping potency above 90% for 30 days at 4 °C and removing ultra-cold logistics from the distribution model.
Read more — Immunology & vaccines03 / Neurology
Transferrin-receptor shuttles deliver oligonucleotides into cortical and hippocampal tissue at levels conventional carriers do not reach, opening durable knockdown strategies for neurodegenerative targets.
Read more — Neurology04 / Rare disease
Automated design-of-experiments compresses formulation screening to weeks, making bespoke carrier development viable for patient populations that traditional programme economics ignore.
Read more — Rare disease05 / Agricultural biotech
Biodegradable nanocarriers deliver RNA-based crop protection directly to plant tissue, cutting active-ingredient load per hectare and reducing run-off into surrounding watersheds.
Read more — Agricultural biotech06 / Environmental sensing
The same quantum-dot chemistry behind our clinical assays detects heavy metals and endocrine disruptors in water samples at parts-per-trillion sensitivity, with results in under ten minutes.
Read more — Environmental sensingA fixed-scope six-week package: receptor mapping, carrier screening and a data-backed go/no-go recommendation.
A joint programme through preclinical validation, with shared IP terms and milestone-based governance.
Access to our ionisable carrier formulations and formulation know-how for your own internal pipeline.
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
